Podcasts about Diabetes Care

Real-talk nutrition with Jenny Smith—simple, practical, no-nonsense. Go tubeless with Omnipod 5 or Omnipod DASH * Eversense CGM Tandem Mobi ** twiist AID System Free Juicebox Community (non Facebook) Medtronic Diabetes Drink AG1.com/Juicebox Use code JUICEBOX to save 40% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6–70 years and 80 people aged 2–5.9 years with type 1 diabetes and 305 people aged 18–75 years with type 2 diabetes. ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.   

Richard Mackey, Chief Technology Officer at CCS, focuses on the challenges faced by patients with diabetes and multiple morbidities, as well as their healthcare providers, in managing their conditions.  CCS has developed the Living Connected approach to connect patients, providers, and payers, and promotes the role that durable medical equipment companies and pharmacists can play in supporting patients and doctors. Recognizing that patients are more than their disease, CCS addresses social determinants of health to provide education and care coordination. Richard explains, "CCS is a company that is in the business of chronic care management. We focus on delivering products and services to patients with a variety of chronic care conditions. But foremost among these for us is diabetes. We're very focused on being able to provide solutions and services for folks who are managing their diabetic condition."  "On the machine learning side, we have a tremendous amount of data and information about how our patients will understand the devices they might be using. For example, continuous glucose monitors or CGMs are an important standard of care that we work with a lot of patients across the US to equip them, find the right device, help them begin using that device, and best understand what it can do and how it can help them make better decisions to manage their conditions." "We might talk to the patient once or twice a month. We might be talking to them multiple times within a quarter. In some cases, we're interacting with a patient more often than others in the ecosystem, maybe more often than even their physician in terms of the number of interactions per month or period, even their health insurance provider. So all that interaction helps give us information and data to draw insights on what those patients might need, what's most important to them, and how they interact with us. We can also work with a variety of other sources to bring information together. And by using the machine learning tools that we've developed, we can understand things that are important to them. So, it might be around the product or specific information related to the plan or the payer they're working with." #CCSMed #Diabetes #ChronicCare #CGM #Healthcare #DigitalHealth #MedicalAI ccsmed.com Download the transcript here

Richard Mackey, Chief Technology Officer at CCS, focuses on the challenges faced by patients with diabetes and multiple morbidities, as well as their healthcare providers, in managing their conditions.  CCS has developed the Living Connected approach to connect patients, providers, and payers, and promotes the role that durable medical equipment companies and pharmacists can play in supporting patients and doctors. Recognizing that patients are more than their disease, CCS addresses social determinants of health to provide education and care coordination. Richard explains, "CCS is a company that is in the business of chronic care management. We focus on delivering products and services to patients with a variety of chronic care conditions. But foremost among these for us is diabetes. We're very focused on being able to provide solutions and services for folks who are managing their diabetic condition."  "On the machine learning side, we have a tremendous amount of data and information about how our patients will understand the devices they might be using. For example, continuous glucose monitors or CGMs are an important standard of care that we work with a lot of patients across the US to equip them, find the right device, help them begin using that device, and best understand what it can do and how it can help them make better decisions to manage their conditions." "We might talk to the patient once or twice a month. We might be talking to them multiple times within a quarter. In some cases, we're interacting with a patient more often than others in the ecosystem, maybe more often than even their physician in terms of the number of interactions per month or period, even their health insurance provider. So all that interaction helps give us information and data to draw insights on what those patients might need, what's most important to them, and how they interact with us. We can also work with a variety of other sources to bring information together. And by using the machine learning tools that we've developed, we can understand things that are important to them. So, it might be around the product or specific information related to the plan or the payer they're working with." #CCSMed #Diabetes #ChronicCare #CGM #Healthcare #DigitalHealth #MedicalAI ccsmed.com Listen to the podcast here

Tim Keller, founder of U.S. Diabetes Care, talks to Shaun about his lifestyle education platform that boasts a 90% decrease rate in Type II diabetes, MAHA's efforts to make Americans healthy, and the intentional poisoning of our children through processed foods.See omnystudio.com/listener for privacy information.

Trump takes on Qatar. PLUS, Todd Sheets, author of 2008: What Really Happened and On Wealth and Progress Newsletter, talks to Shaun about the housing crisis of 2008 and why we have given control of interest rates to a small body of unelected people in The Fed. And Tim Keller, founder of U.S. Diabetes Care, talks to Shaun about his lifestyle education platform that boasts a 90% decrease rate in Type II diabetes, MAHA's efforts to make Americans healthy, and the intentional poisoning of our children through processed foods.See omnystudio.com/listener for privacy information.

2520 Accessible Devices Change Diabetes Care (May 14, 2025) Show Notes How do visually impaired individuals manage diabetes independently? Hosts Nancy and Peter Torpey talk with Veronica Elsea and Patricia Maddix about accessible insulin pumps, continuous glucose monitors, and their advocacy work for non-visual medical tools. Both women share their personal journeys navigating diabetes care … Continue reading 2520 Accessible Devices Change Diabetes Care (May 14, 2025) →

Ryan Paul discusses disparities in diabetes care, focusing on how technology can reduce the equity gap.

In this special episode on Hypercortisolism in Diabetes our host, Dr. Neil Skolnik, will discuss new evidence showing the surprising prevalence of Hypercortisolism in people with uncontrolled Type 2 Diabetes.  This special episode is supported by an independent educational grant from Corcept. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John Buse MD – The Verne S. Caviness Distinguished Professor and director of the Diabetes Center at the University of North Carolina at Chapel Hill School of Medicine, a past president of medicine & science at the American Diabetes Association (ADA), and recipient of the ADA Outstanding Achievement in Clinical Diabetes Research Award, Reference: Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care dc242841 https://doi.org/10.2337/dc24-2841  

Morning News then Tim Keller, Chairman and Founder, U.S. Diabetes Care dot com - Discusses the Trump EO lowering prescription drug prices, will it work? ALso the challenge of diabetes treatment and how his app and clinic operates.

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.     Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) - NEJM 2.     Diabetes and Anemia – Diabetes Care 3.     Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials – Diabetes Care 4.     Cardiovascular and Kidney Outcomes and Mortality With Long- Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials – Diabetes Care 5.     Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes - NEJM   For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

In this special episode on Early Identification and Delay of Type 1 Diabetes, Dr. Neil Skolnik this emerging area with Dr. Jay Shubrook. This special episode is supported by an independent educational grant from Sanofi. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Jay Shubrook, D.O.  - Professor and Director of Diabetes Services, Touro University. Past  Chair, The American Diabetes Association Primary Care Advisory Group, Past Chair of the American College of Diabetology.   Selected References and Resources referred to the in the Podcast: Webinar Registration (Apr 28, 2025 10:00 AM): Early Detection Saves Lives: Implementing Type 1 Diabetes Screening in Pediatric and Primary Care References: Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetes Care 2024;47(8):1276–1298 An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med 2019;381:603-613 Resources for Auto-antibody Testing: Type 1 Diabetes TrialNet Centers of Excellence Locations Type 1 Risk test         Trialnet  

In this episode of The Healthy Project, host Corey Dion Lewis sits down with Brian Foster to explore how community health workers are transforming diabetes care—especially in underserved communities. Brian shares his personal journey with type 1 diabetes and his work with the American Diabetes Association. They discuss the connection between diabetes and heart disease, health equity, patient trust, and why community-based care is critical for improving outcomes.Topics: type 1 diabetes, diabetes education, community health workers, healthcare access, health equity, social determinants of health, American Diabetes Association, chronic disease management, public health policy, Black health equity, Healthy Project Podcast ★ Support this podcast ★

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.    Coronary Artery Calcium-Guided Primary Prevention Strategy 2.    Health-Related Quality of Life and Health Utility after Metabolic/Bariatric Surgery vs. Medical/Lifestyle Intervention in Individuals with Type 2 Diabetes and Obesity 3.    Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study 4.    Self-Monitored Blood Glucose and Continuous Glucose Monitoring in Youth with Type 1 Diabetes and Medicaid Insurance 5.     Gestational Diabetes to Type 2 Diabetes—Is Poor Sleep to Blame?   For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

In this episode, Janice Dada, a dietitian specializing in eating disorders, diabetes care, and intuitive eating, shares her journey and explains how intuitive eating offers a fresh, non-diet approach to managing health. We explore how this framework works alongside chronic illness, dietary restrictions, and cravings, and discuss the importance of listening to the body's hunger and fullness signals. Janice also offers insights into the future of intuitive eating in chronic illness management.

Mándanos un mensaje¿Alguna vez has sentido que sigues todas las reglas pero tu cuerpo no responde como esperabas? La respuesta podría estar en tus biomarcadores, esas pequeñas señales químicas que revelan la verdad sobre tu salud mucho antes que cualquier síntoma visible.Organizaciones de saludAmerican Diabetes Association (ADA): https://diabetes.org/American Heart Association (AHA): https://www.heart.org/World Health Organization (WHO): https://www.who.int/National Institutes of Health (NIH): https://www.nih.gov/Centers for Disease Control and Prevention (CDC): https://www.cdc.gov/Endocrine Society: https://www.endocrine.org/American College of Rheumatology: https://www.rheumatology.org/American Association for the Study of Liver Diseases: https://www.aasld.org/Estudios científicos específicosHemoglobina A1C: American Diabetes Association. (2021). Glycemic Targets: Standards of Medical Care in Diabetes. Diabetes Care, 44(Supplement 1): S73-S84.Ferritina y rendimiento: Sim, M., et al. (2019). Iron considerations for the athlete: a narrative review. European Journal of Applied Physiology, 119(7): 1463-1478.Miocinas: Pedersen, B. K. (2019). Physical activity and muscle-brain crosstalk. Nature Reviews Endocrinology, 15(7): 383-392.Perfil lipídico y riesgo cardiovascular: Grundy, S. M., et al. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology, 73(24): e285-e350.Vitamina D: Holick, M. F., et al. (2011). Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 96(7): 1911-1930.Enzimas hepáticas: Kwo, P. Y., et al. (2017). ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. The American Journal of Gastroenterology, 112(1): 18-35.Ácido úrico y enfermedad cardiovascular: Borghi, C., et al. (2020). Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiology, 145(1): 1-10.Variabilidad de frecuencia cardíaca: Shaffer, F., & Ginsberg, J. P. (2017). An Overview of Heart Rate Variability Metrics and Norms. Frontiers in Public Health, 5: 258.Support the showInstagram: andieillanesPágina web: andieillanes.com.mx

On this episode of The Huddle, Chris Memering, MSN, RN, CDCES, BC-ADM, talks about the value that diabetes care and education specialists bring to the inpatient care setting. She outlines the importance of continuity of care between the inpatient and outpatient setting, how DCES in inpatient help increase patient satisfaction and safety, and how others in the inpatient setting can demonstrate their value to their hospital leadership.Learn more about how to showcase the value of the diabetes care and education specialty in our value toolkit created especially for ADCES members. Log in here to view the toolkit:  Showcase Value ToolkitOr click here to become an ADCES member to access helpful resources like this one: MembershipLearn more about ADCES' inpatient certificate program focused on knowledge and skills necessary for effective inpatient diabetes care: https://www.adces.org/store/certificate-programs/detail/inpatient-certificate-program-transforming-care-and-enhancing-lives Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

I'm excited to welcome Jessica Jones, a Registered Dietitian, Certified Diabetes Educator, and co-founder of Diabetes Digital, a virtual nutrition counselling company that provides weight-inclusive, culturally responsive care for people with diabetes and other health conditions. Jessica is also the co-creator of the Food Heaven brand, which has garnered over 250K followers and 5 million podcast downloads, with features in Bon Appétit, Oprah Magazine, and more!We dive deep into:Jessica's journey from journalism to dietetics and how it shaped her approach to careThe creation of Diabetes Digital and its focus on weight-inclusive, culturally responsive care for people with diabetesHow to navigate a quantifiable disease like diabetes while honouring individual experiencesPersonalizing patient care and the importance of meeting each person where they areJessica's experience with hormonal and blood sugar changes and what she's learnedPractical tips for stabilizing blood sugar and managing health in an empowering, sustainable way

In a previous episode, Dr. Sergio Zanotti explored the importance of challenging dogma, particularly when the supporting evidence is weak or absent. Today, he continues that discussion by examining critical care practices that persist despite a lack of strong scientific validation. He's joined by Dr. Mervyn Singer, an internationally recognized leader in critical care medicine. Dr. Singer is a professor of intensive care medicine at University College London and a distinguished clinician, researcher, and educator. Through his research, publications, and dynamic presentations, he has inspired Dr. Zanotti — and countless intensivists worldwide — to think critically, challenge conventions, and push the boundaries of our field. Additional resources: Challenging management dogma where evidence is non-existent, weak, or outdated: part II. DA Hofmaennner and M. Singer. Intensive Care Med2024: https://pubmed.ncbi.nlm.nih.go Challenging management dogma where evidence is non-existent, weak, or outdated. DA Hofmaennner and M. Singer. Intensive Care Med 2022: https://pubmed.ncbi.nlm.nih.gov/35303116/ Biomarker-Guided Antibiotic Duration for Hospitalized Patients with Suspected Sepsis. The ADAPT-Sepsis Randomized Clinical Trial. JAMA 2025: https://pubmed.ncbi.nlm.nih.gov/39652885/ Hyperglycemic Crises in Adults with Diabetes: A Consensus Report. Diabetes Care 2024: https://pubmed.ncbi.nlm.nih.gov/38907161/ Books and music mentioned in this episode. Influenza: The Hundred-Year Hunt to Cure the 1918 Spanish Flu Pandemic. By. Jeremy Brown: https://amzn.to/3Ftb0mO Beethoven: 9 Symphonies / Karajan 1963: https://amzn.to/3R1M9ZO

Maintaining a healthy weight, eating nutritious foods, and avoiding fast food are key to reducing the risk of diabetes. Currently, nearly one in four adults over 18 is living with diabetes. Women are especially vulnerable during pregnancy due to hormonal changes, making regular screening crucial. Consulting a doctor ensures tailored guidance for managing gestational diabetes effectively. Uncontrolled blood sugar levels pose serious risks during surgery. While sterile procedures generally avoid infections, high blood sugar can delay healing, increase infection risks, and complicate recovery. In surgeries like bypass operations, infected stitches may lead to scarring or further complications. Stabilizing blood sugar before surgery and maintaining it during anaesthesia are vital for safe outcomes. Gestational diabetes results from hormones like human placental lactogen (HPL) reducing insulin effectiveness. During pregnancy, the pancreas must produce up to 50% more insulin to meet rising demands. If beta cells cannot keep up, blood sugar levels rise, stressing the body and increasing diabetes risk. High blood sugar damages nerves, impairing their function and delaying wound healing due to reduced immunity. Nerve damage often starts symmetrically but may affect only one foot. Managing blood sugar is essential for nerve health, faster healing, and preventing infections Recorded on: 11.12.2024 Recorded at: Akashwani Nagpur

In this special episode on Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) our host, Dr. Neil Skolnik will lead a case-based discussion on HFpEF, presenting challenges and integration of emerging evidence into clinical practice. This special episode is supported by an independent educational grant from Roche. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Susan Kuchera, M.D. - Clinical Assistant Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University and Program Director of the Family Medicine Residency at Jefferson Health Abington. Muthu Vaduganathan M.D. - Cardiologist and Co-Director, Center for Cardiometabolic Implementation Science at Brigham and Women's Hospital and Harvard Medical School; Associate Editor of the Journal of the American College of Cardiology.   Selected references referred to the in the Podcast: Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association.  Diabetes Care 2022  2023 American College of Cardiology Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (HFpEF). Journal of the American College of Cardiology 2023 Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiology 2022;7(12):1259-1263    

Type 2 diabetes is a metabolic disorder characterised by high blood sugar levels due to insulin resistance or insufficient insulin production. It's a growing global health concern. While diet, exercise and medication form the cornerstone of diabetes management, researchers are continually exploring new avenues to improve blood sugar control. One such area gaining traction is the use of probiotics that can alter gut and metabolic health. But can these tiny microorganisms make a meaningful difference for people with type 2 diabetes? That's what I explore in this episode.Links referred to in the podcastReview of the effects of probiotics on glucose control in T2DM https://pubmed.ncbi.nlm.nih.gov/39349104Episode transcriptTo access the full episode transcript, go to the following link and select the individual podcast episode and then click on the ‘Transcript' tab https://thinkingnutrition.buzzsprout.comConnect with meInstagram doctimcroweFacebook Thinking NutritionX CroweTim

In this episode of Healthcare on the Rocks: Employee Benefits with a Twist, hosts Brittany Hardaway and Rachael Baumgartner sit down with Dr. Janet Young, Clinical Analytics Advisor at Springbuk, to unpack a growing challenge for employers: the rising costs of diabetes care. ‍Dr. Young shares that diabetes-related spending has surged by 38% over the past three years—far outpacing other chronic conditions. A major driver? The skyrocketing use of GLP-1 agonists, medications originally developed for diabetes but now widely used for weight loss. "More than 40% of members with type 2 diabetes filled a prescription for GLP-1s last year—double the rate from four years ago," she notes. While these medications offer powerful benefits, including improved glucose control and cardiovascular protection, their costs continue to climb, creating tough decisions for employer-sponsored health plans.As employers strategize for the future, Dr. Young emphasizes three key priorities: tracking diabetes trends, proactively addressing prediabetes, and ensuring equitable access to care.The conversation also explores the expanding role of continuous glucose monitors (CGMs) beyond type 1 diabetes patients. These devices, which eliminate the need for fingersticks, are gaining traction among insulin-dependent type 2 diabetics and could have broader applications—potentially even helping prediabetic individuals prevent disease progression. Dr. Young also highlights the stark disparities in diabetes treatment based on social determinants of health (SDOH), with more vulnerable populations less likely to access newer medications and monitoring tools. Key TakeawaysDiabetes costs are rising fast – Diabetes spending jumped 38% over three years, driven largely by the rising use of GLP-1 agonists.GLP-1 medications are in high demand – More effective than older treatments and linked to weight loss, GLP-1s are now used by over 40% of type 2 diabetics.CGMs are expanding beyond insulin users – Real-time glucose tracking is gaining popularity and could play a role in prediabetes prevention.Social determinants of health matter – Diabetes rates double in high-vulnerability populations, yet these groups have less access to newer treatments.Employers should focus on three things – Monitor diabetes trends, tackle prediabetes early, and reduce treatment disparities.Stay in Touch!Connect with Janet Young on LinkedInGet the complete 2025 Employee Health Trends report and other related resourcesConnect with our co-hosts Brittany Hardaway and Rachael BaumgartnerHave feedback, questions, or suggestions for show ideas? Send them to us at podcast@springbuk.com. Please rate and review us on your favorite podcast platform, and share it with your friends and colleagues. We appreciate you and thank you for listening! Theme music: "Overboard" by Stay Outside

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.     Dapagliflozin plus calorie restriction for remission of type 2 diabetes 2.     Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity 3.     Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes 4.     Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes 5.     Use of SGLT2i Versus DPP-4i as an Add-On Therapy and the Risk of PAD-Related Surgical Events (Amputation, Stent Placement, or Vascular Surgery)   For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

In this episode, Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, a Gerontological Nurse Practitioner, and member of the GAPNA Communication Team, talks with Dr. Michelle Talley, PhD, CRNP, ACNP‐BC, FAANP, FAAN, FNAP, an Associate Professor and Associate Dean for Clinical and Global Partnerships at the University of Alabama at Birmingham School of Nursing. She also serves as the Director of the PATH Clinic.Dr. Michelle Talley, PhD, CRNP, ACNP‐BC, FAANP, FAAN, FNAP, is an Associate Professor and Associate Dean for Clinical and Global Partnerships at the University of Alabama at Birmingham School of Nursing. She also serves as the Director of the PATH Clinic.Dr. Cassandra Vonnes, DNP, GNP-BC, APRN, AOCNP, CPHQ, FAHA, is the Nurses Improving Care for Healthsystem Elders (NICHE) Coordinator, Geriatric Oncology, at the Moffitt Cancer Center, in Tampa, Florida. She is a member of the Gerontological Advanced Practice Nurses Association Communication Team and is a host of the GAPNA Chat podcast series.Discover GAPNA: https://www.gapna.org/Production management by Anthony J. Jannetti, Inc., for the Gerontological Advanced Practice Nurses Association.Opening Music by:Optimistic / Inspirational by Mixaund | https://mixaund.bandcamp.com
Music promoted by https://www.free-stock-music.comClosing Music by:Scott Holmes.http://www.scottholmesmusic.com

Der er ingen tvivl om at det er usundt at være tyk, eller er der? Vi får tudet ørene fulde af at det er usundt at være tyk, at det er forkert at være tyk og at alle ens problemer løser sig hvis bare man taber sig, men hvorfor det er faktuelt forkert forklarer Rasmus Køster-Rasmussen i denne episode. Rasmus der er podcastvært på podcasten Radio Ligevægt, og læge og forsker med speciale i vægtudvikling, har selv skulle se det vægtparadigme vi har i vores samfund dybt i øjnene for at forstå, hvor mange fejlslutninger der florerer omkring det at være tyk og det at være usund. I denne episode centrerer vi os om spørgsmålet: Er det usundt at være tyk, og her forklarer Rasmus blandt andet, at hvis vi skal vurdere om et vægttab er sundhedsgavnligt eller sundhedsskadeligt, bliver vi nødt til at vægte skadevirkninger overfor gavnlige effekter, men hvad, kan der være skadevirkninger forbundet med vægttab tænker du måske. Hør svaret i episoden.Det kommer vi blandt andet ind på i episoden: Censur i forskningen omkring BMI og dødOm der er forskel på tilsigtede og utilsigtede vægttab i relation til øget dødelighedOm vægttab er vejen til mere sundhedHvordan det som sundhedsprofessionel kan være udfordrende at formidle paradigmeskiftVægttabsparadigmetOm vi tager modet fra folk når vi fortæller dem at det ikke er usundt at være tykHvordan alle slankekure virker på kort sigt og ikke på lang sigtHvordan både en slankekur og en livsstilsintervention er synonymer for energirestriktionerOm det er muligt at lave indsatser der kan hjælpe mennesker med at holde vægten nedeHvad der gør at nogle mennesker kan holde et vægttabOm vægttab har en effekt på risikoen for blodpropperHvordan man øger sundheden hvis det ikke skal handle om vægttabHvilke fysiske og psykiske skadevirkninger der kan være forbundet med vægttabOm en høj BMI er forbundet med øget dødelighed og kardiovaskulær sygdomOm risikoen for tidlig død forbundet med en høj vægt reguleres, når vi justerer for andre faktorer så som ulighed i sundhed og vægtstigmatiseringHvordan du kan lære at slutte fred med din krop som den erI episoden deler jeg at du kan teste hvor intuitivt dit spisemønster er via min test: Spiser du intuitivt. Testen kan du hente via linket her.Et randomiseret kontrolleret forsøg viste at en intensiv livsstilsintervention med fokus på vægttab ikke reducerede antallet af kardiovaskulære sygdomme hos overvægtige voksne med type 2-diabetes (1)Intensive livsstilsinterventioner ændrer umiddelbart ikke på risikoen for dødelighed blandt mennesker med prædiabetes eller type 2-diabetes (2)Et stort systematisk review der samlede forskellige vægttabsprogrammer viser et gennemsnitligt vægttab på 1,8 kilo (3)Vægtdiskrimmination er forbundet med en næsten 60% øget risiko for dødelighed (4)Hvis et vægttab skal bevares skal energirestriktionen vedholdes, i en sådan grad at det i mange tilfælde vil kunne sammenlignes med anorektisk adfærd, og små vægtudsving skal monitoreres hurtigt  (5,6)Energirestriktion er relateret til afminiralisering af knoglerne (7)Kilder:1: Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013 2: Zucatti et al. Long-term Effect of Lifestyle Interventions on the Cardiovascular and All-Cause Mortality of Subjects With Prediabetes and Type 2 Diabetes: A Systematic Review and Meta-analysis. Diabetes Care. 20223: Madigan et al. Effectiveness of weight management interventions for adults delivered in primary care: systematic review and meta-analysis of randomised controlled trials. BMJ. 2022 4: Sutin AR, Stephan Y, Terracciano A. Weight Discrimination and Risk of Mortality. Psychol Sci. 2015 5: Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr 20056: Weightloss maintenance for 10 years in the National Weight Control Registry. Am J Prev Med. 20147: Johnson and the Look AHEAD Study Group. The Effect of Intentional Weight Loss on Fracture Risk in Persons With Diabetes

Join Sandra & Dr. Nykkia Sellers, a board-certified NP and diabetes expert, as she shares how game-changing treatments like GLP-1 meds (hello, Ozempic!) and personalized care are transforming diabetes management. From reversing high A1Cs to the future of endocrinology and chronic disease management, this episode is a must-listen for NPs ready to elevate their practiceFollow Nykkia on Instagram: @thediabeteswellnessNPCheck out Nykkia's Diabetes Care Practice: www.mydcwellness.comGo to NP Charting school's website and get  your comprehensive list of smart phrases  that you can copy & paste into your EHR to immediately save time charting! www.npchartingschool.comCheck out our eBooks designed specifically for NP students navigating the clinical setting! https://bit.ly/SuccessNPebook

Timestamps:7:55 - Is Ypsomed just an insulin company?10:12 - Selling B2B and B2C simultaneously18:33 - Doing an IPO in 200420:20 - How to make your stock 7x22:47 - Getting into regional politicsThis episode was produced in collaboration with startup days, taking place this year on May 14th 2025. Click ⁠here⁠ to purchase your ticket.About Simon Michel:Simon Michel is the CEO of Ypsomed, the leading developer and manufacturer of injection systems for self-medication. He is also the head of Swiss Startup Supporters, a new startup days initiative. Simon holds an MA in Media and Communications Management from HSG and worked for the consultancy Arthur D. Little and the telecommunications company Orange Communications SA before joining his father's company, Ypsomed, in 2006.In 1984, a company named Disetronic was founded by the brothers Willy and Peter Michel (Willy being Simon's father), in Burgdorf, Switzerland. Disetronic was the first company to introduce a micro insulin pump to the medtech/pharma market. Besides its infusion systems, Disetronic also specialised in injection systems. In 2003, co-founder and main shareholder Willy Michel sold Disetronic's infusion business to Roche and kept the injection business — that's how Ypsomed was born.Simon first joined Ypsomed as a Business Development Manager of Diabetes Care, and rose through the ranks until he became CEO in 2014. He credits this gradual rise, based on concrete achievements within the company, as the reason for his easy integration in its team. Nowadays Ypsomed focuses on the treatment of chronic diseases such as diabetes, obesity, polyarthritis, Alzheimer and migraines. On 22 September 2004, Ypsomed was registered on SIX Swiss Exchange under the ticket SWX:YPSN.Simon is also affiliated with FDP (The Liberals party) and is a member of Switzerland's National Council. When asked about Switzerland's political strengths and weaknesses, he identified the following strengths: Strong majority support: Switzerland takes an average of 6 years to get a new law approved. This makes its political system quite slow, but this slowness has the advantage of ensuring majority support for many of the laws approved. Strong R&D: The Swiss government invests CHF 10B per year in education and research, out of a CHF 90B budget. This results in a robust education system. Independence and neutrality, which give Switzerland international credibility.Simon also identified 2 weaknesses in Switzerland's political system: Speed: This system is, indeed, quite slow, and unnecessarily so, in Simon's opinion. Left vs Right disagreements: Simon opposes the Swiss left's ideas of rebuilding Switzerland as a state-run operation less reliant on private enterprise. He considers this a political weakness.The cover portrait was edited by ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.smartportrait.io⁠⁠⁠‍Don't forget to give us a follow on⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠,⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠and ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, so you can always stay up to date with our latest initiatives. That way, there's no excuse for missing out on live shows, weekly giveaways or founders' dinners.

In this episode of Your Diabetes Insider, we chat with Dr. Michael Devano, a family medicine resident, powerlifting enthusiast, and passionate advocate for diabetes care. Dr. Devano shares his unique perspective on how exercise can improve diabetes management and what to look for when choosing a healthcare provider. If you've ever felt frustrated with your doctor visits, this episode is packed with valuable tips to help you make the most of your appointments and build a better relationship with your care team! Want the best blood sugars you've ever had while enjoying great food? Peep this: https://www.yourdiabetesinsider.com/coaching   Check him out on Instagram @danny_delifto: https://www.instagram.com/danny_delifto   RESOURCES: Download these FREE guides that will help you on your diabetes, nutrition, and exercise journey! https://www.yourdiabetesinsider.com/free-stuff Join our EXCLUSIVE Facebook group! https://www.facebook.com/groups/266766620895432 Watch my food breakdowns here → https://www.youtube.com/@yourdiabetesinsider   LET'S TALK! Instagram: @manoftzeel Tiktok: @manoftzeel

In this special edition of Diabetes Core Update, host Neil Skolnik, MD, explores the timely and critical topic of compounded medications in diabetes care. In this episode Dr. Skolnik moderates a discussion between a family doctor, a patient, and a pharmacist about practical decision making around the topic of compounded medication for the treatment of overweight and obesity. This special edition of Diabetes Core Update is supported by Lilly. Presented by: Neil Skolnik, MD – Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington–Jefferson Health John Hertig, PharmD, MS, CPPS – Associate Professor, Butler University College of Pharmacy and Health Sciences Susan Kuchera, MD - Clinical Assistant Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University and Program Director of the Family Medicine Residency at Jefferson Health Abington. Lisa Kessler MS, CCC-SLP - Infant-toddler Homebased Pediatric Speech-Language Pathologist Compounded GLP 1 and Dual GIP/GLP 1 Receptor Agonists: A Statement from the American Diabetes Association. Diabetes Care December 2, 2024;  dci240091 https://doi.org/10.2337/dci24-0091 PubMed: 39620926 FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.  US FDA Website ( current as of 12/18/2024)

Michael See MS, ACSM-CEP, NBCHWC, CDES joins the Huddle to share his expertise and experiences in bringing physical activity to people with type 2 diabetes who also have physical limitations. He covers topics like how to assess physical limitations, their prevalence in people with type 2 diabetes, and how to use a motivational interviewing approach in conversations with your clients. This episode was made possible with support from Lilly, A Medicine Company. Learn more about this topic in our latest patient/client handout (support for the development of this handout was provided by Lilly, A Medicine Company): adces_tipsheet_physical_activity2.pdf ReferencesAmerican Diabetes Association Professional Practice Committee; 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2024. Diabetes Care 1 January 2024; 47 (Supplement_1): S77–S110.Ahmad E, Sargeant JA, Yates T, Webb DR, Davies MJ. Type 2 Diabetes and Impaired Physical Function: A Growing Problem. Diabetology. 2022; 3(1):30-45. https://doi.org/10.3390/diabetology3010003Angulo, J., Assar, M. E., Álvarez-Bustos, A., & Rodríguez-Mañas, L. (2020). Physical activity and exercise: Strategies to manage frailty. Redox Biology, 35. https://doi.org/10.1016/j.redox.2020.101513Colberg SR, Sigal RJ, Yardley JE, et al. Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065-2079. doi:10.2337/dc16-1728O'Neill D, Forman DE. The importance of physical function as a clinical outcome: Assessment and enhancement. Clin Cardiol. 2020;43(2):108-117. doi:10.1002/clc.23311Pedersen BK, Saltin B. Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports. 2015;25 Suppl 3:1-72. doi:10.1111/sms.1258136-Item Short form survey instrument (SF-36). Available at: https://www.rand.org/content/dam/rand/www/external/health/surveys_tools/mos/mos_core_36item_survey.pdf (Accessed: 21 October 2024). Physical activity vital sign. Available at: https://www.exerciseismedicine.org/wp-content/uploads/2021/04/EIM-Physical-Activity-Vital-Sign.pdf (Accessed: 21 October 2024).  Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.     Large Language Model GPT-4 Compared to Endocrinologist Responses on Initial Choice of Antidiabetic Medication   2.     Long term health outcomes in people with diabetes 12 months after hospitalization with COVID-19 in the UK: a prospective cohort study 3.     Risk of nephrolithiasis associated with SGLT2 inhibitors versus DPP4 inhibitors among patients with type 2 diabetes: a target trial emulation study 4.     Early Screening for Latent Autoimmune Diabetes in Adults to Improve Care—Beyond the Routine 5.     Project ECHO Diabetes Trial Improves Outcomes for Medically Underserved People   For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Eileen Egan, DNP, FNP-C, BC-ADM, CDCES, FADCES joins The Huddle to share her expertise about the interplay between weight and glycemic management in people with Type 2 diabetes, the importance of meeting glycemic and weight goals early after a Type 2 diabetes diagnosis, as well as best practices for helping people stay motivated and engaged. This episode was made possible with support from Lilly, A Medicine Company. Learn more about this topic in this accompanying patient/client handout (support for the development of this handout was provided by Lilly, A Medicine Company): adces_tipsheet_early_control2.pdf References:American Diabetes Association. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes- 2024. Diabetes Care, 47(1): S145-S157.Center for Disease Control and Prevention. Adult overweight and obesity. https://www.cdc.gov/obesity/basics/adult-defining.htmlDCCT/EDIC study research group. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. Diabetes Care. 2016;39(5):686-693. Gregg E, Jakicic J, Blackburn G, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post hoc analysis of the Look AHEAD randomized clinical trial. Lancet Diabetes Endocrinol. 2016; 4(11): 913-921.Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases. Int J Mol Sci. 2021. 27;22(21):11629.Howard BV, Ruotolo G, Robbins DC. Obesity and dyslipidemia. Endocrinol Metab Clin North Am. 2003;32(4):855-867. Jin X, et al. Pathophysiology of obesity and its associated diseases. Acta Pharm Sin B. 2023;13(6):2403-2424.  Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2019;42(3):416-426.Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.Lancet Diabetes Endocrinol. 2019;7(5):344-355.Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022 Jan 22;399(10322):394-405. doi: 10.1016/S0140-6736(21)01919-X. Epub 2021 Sep 30. Erratum in: Lancet. 2022 Jan 22;399(10322):358. PMID: 34600604Rachel G. Miller, Trevor J. Orchard; Understanding Metabolic Memory: A Tale of Two Studies. Diabetes 1 March 2020; 69 (3): 291–299. https://doi.org/10.2337/db19-0514Ross, R., Neeland, I.J., Yamashita, S. et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol16, 177–189 (2020). https://doi.org/10.1038/s41574-019-0310-7Thom G, McIntosh A, Messow CM, et al. Weight loss-induced increase in fasting ghrelin concentration is a predictor of weight regain: Evidence from the Diabetes Remission Clinical Trial (DiRECT). Diabetes Obes Metab. 2021;(23):711-719.Tsai AG, Bessesen DH. Obesity. Ann Intern Med. 2019;170(5):ITC33-ITC48.Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-154.World Health Organization. Obesity. https://www.who.int/health-topics/obesity#tab=tab_1 Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Dr. Sam Scott holds a PhD in Exercise Physiology and is the CEO of Enhance-d - a startup aimed at helping people with diabetes to exercise safely and effectively.  Sam has worked with high level athletes and general population folks with Type 1 and Type 2 diabetes in helping them train and perform safely and effectively in sport and everyday life. Many people around the world are unfortunately affected by either Type 1 or Type 2 diabetes. While management of these conditions is possible, it's not exactly intuitive or widely known. Sam and I sat down to discuss this today. Especially how exercise can help and greatly positively impact people. There are important considerations to make when just starting out, and there is certainly a bit of a learning curve. We cover all of this and more.We also discuss Sam's company, Enhance-d which is a digital ecosystem that will simplify the tracking and analysis of all relevant data (glucose levels, insulin, nutrition etc) to empower those living with diabetes to make informed decisions, optimize their performance, and be part of a community to have ongoing support. You can download the app here and follow along on social media for any updates. The best way to support the podcast is to share the episode with a friend. You can support yourself and the podcast by applying for 1:1 online coaching here. Grab my FREE Protein Cheat Sheet HERE.  Grab my FREE Muscle Building Workout HERE. Join 1000's of others in receiving the best fitness tips, tools and tactics for free via the Sunday Meal Prep newsletter. Share this episode with a friend who would enjoy or benefit from it! Comments, questions, and feedback are greatly appreciated. If you enjoy this podcast, I would be extremely grateful if you subscribed and left a short review on iTunes or rating on Spotify.  It really helps to spread the message and ultimately help more people.  Website danielyores.com Connect with me on Instagram @danielyoresConnect with me on X @danielyores Podcast Cover Art by @octopuslegss

This is the second episode in a special three-part series of the Diabetes Core Update podcast, focusing on heart failure with preserved ejection fraction (HFpEF) in people with diabetes. Sponsored by Roche, this series provides primary care clinicians and healthcare professionals with actionable insights into screening, diagnosis, and treatment of HFpEF, a major complication in cardiometabolic care. In this episode, host Dr. Neil Skolnik discusses treatment strategies for HFpEF with expert guest Dr. James Jannuzzi, a cardiologist and professor at Harvard Medical School. Building on the first episode's discussion of screening and diagnosis, this installment highlights evidence-based treatments and their integration into diabetes care. Presented by: ·       Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health ·       James Jannuzzi, MD, Professor of Medicine at Harvard Medical School, Staff Cardiologist at Massachusetts General Hospital, and Senior Cardiometabolic Faculty at Baim Institute for Clinical Research. Selected references: ·       Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care 2022 ·       2023 American College of Cardiology Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology 2023 Tune in to the third and final episode, where the series will explore clinical decision-making and case-based applications of HFpEF treatments. This special edition of Diabetes Core Update is sponsored by Roche.  

On our latest episode of The Huddle, Sheetal Shah, founder of MettaHealth Partners discusses the evolving realm of AI, the role DCESs and other health care professionals can play in embracing and adopting AI technology, and the importance of keeping a human element in the technology.Learn more about MettaHealth Partners here: MettaHealth PartnersLearn more about the National Institute of Standards and Technology (NIST) here: National Institute of Standards and TechnologyStay up to date on all things related to diabetes technology on danatech: Diabetes technology for healthcare professionals | Danatech Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Welcome to this special edition of Diabetes Core Update, where host Dr. Neil Skolnik takes a deep dive into the transformative role of continuous glucose monitoring (CGM) in diabetes care. Through engaging conversations with two leading experts, Dr. Skolnik explores the latest advancements in CGM technology, its clinical benefits, and its growing accessibility. Packed with valuable insights, this episode is an essential listen for healthcare professionals navigating the evolving landscape of diabetes management. This episode is sponsored by Dexcom, the #1 HCP-recommended CGM brand* and creators of Dexcom G7. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Eden Miller, DO, Founder of Diabetes Nation, a nonprofit organization, and CEO of Diabetes and Obesity Care, Bend, Oregon Eugene Wright, MD, Medical Director of Performance Improvement, Charlotte Area Health Education Center, Charlotte, North Carolina; Consulting Associate, Department of Medicine, Duke University Medical Center, Durham, North Carolina Select resources and studies mentioned in the podcast: https://pro.diabeteswise.org/en/resources https://www.aafp.org/pubs/fpm/issues/2024/0100/continuous-glucose-monitoring.pdf https://www.adces.org/danatech/glucose-monitoring/continuous-glucose-monitors-(cgm)/cgm-insurance-coverage-look-up Miller E, Chuang JS, Roberts GJ, Nabutovsky Y, Virdi N, Wright Jr. EE: Association of changes in A1C following continuous glucose monitoring acquisition in people with sub‐optimally treated type 2 diabetes taking GLP‐1 RA therapy. Diabetes Therapy 2024;15:2027-2038 https://doi.org/10.1007/s13300-024-01619-1 This special episode of Diabetes Core Update is sponsored by Dexcom, the #1 HCP-recommended CGM brand* and creators of Dexcom G7 (1). Dexcom G7 is a continuous glucose monitoring system, designed for patients with all types of diabetes (2). The American Diabetes Association recommends the use of CGM in people with diabetes, as CGM is clinically proven to lower A1C, reduce hyper- and hypoglycemia, and increase time in range (3). Getting started with Dexcom G7 is easy, with only one prescription needed. Visit https://Dexcom.com/ADA for prescribing information and to sample Dexcom G7 for free. *Based on a comparison in NPS scores across major CGM brands. References 1. Seagrove Partners, LLC. Seagrove Partners HCP Perspectives. 2022 2. Dexcom. Dexcom G7 User Guide. 2023 3. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2025. Diabetes Care 2025;48(Suppl. 1):S1–S352

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.     Results from a Randomized Trial of Intensive Glucose Management Using CGM Versus Usual Care in Hospitalized Adults with Type 2 Diabetes: the “TIGHT” Study 2.     Tirzepatide for Obesity Treatment and Diabetes Prevention  3.     Intensive Blood-Pressure Control in Patients with Type 2 Diabetes 4.     Association of Insulin Resistance With Radiographic Lung Abnormalities and Incident Lung Disease 5.     Association Life-course Associations between Ambient Fine Particulate Matter and the Prevalence of Prediabetes and Diabetes 6.     Semaglutide in Persons with Obesity and Knee Osteoarthritis   For more information about each of ADA's science and medical journals, please visit www.diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Michael Dardenelle was diagnosed with type 1 diabetes in 1956. In this episode, he reflects on the remarkable evolution of diabetes treatment and technology over the decades, while sharing his personal health challenges, including living with neuropathy. Michael's journey is both inspiring and insightful—a must-watch for anyone interested in diabetes care. Be sure to tune in next week as Michael returns to discuss his transition from the Tandem t:slim X2 to the Medtronic 780G!   Please fill out our 2024 Diabetech Podcast Survey   Learn about Omnipod 5 (today's sponsor)*   T1D Exchange Registry Sign up  (US only)   Read our Blog + Join the Newsletter    Support Diabetech on Patreon  | Diabetech Community Discord   Follow me here: Instagram | Tik Tok | YouTube | Facebook   Watch the Podcast on Youtube   DISCLAIMERS: This podcast is not medical advice and is for educational purposes only. Always consult with your doctor before making changes to your health care.   *10-day trial eligibility may vary. Full terms and conditions apply. Visit omnipod.com/diabetech for clinical disclaimers, terms and important safety information. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.

In this special edition of Diabetes Core Update, host Neil Skolnik, MD, explores the timely and critical topic of compounded medications in diabetes care. Dr. Skolnik is joined by John Hertig, PharmD, MS, CPPS, Associate Professor at the Butler University College of Pharmacy and Health Sciences, and Ed Hernandez, Executive Vice President and President of Manufacturing Operations at Eli Lilly & Company. Together, they discuss the role of compounded medications, the benefits and risks associated with their use, and the importance of ensuring quality and safety standards in the compounding process. This episode offers valuable insights for clinicians navigating the complexities of compounded therapies and provides practical considerations for patient care. This special edition of Diabetes Core Update is supported by Lilly. Presented by: Neil Skolnik, MD – Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington–Jefferson Health John Hertig, PharmD, MS, CPPS – Associate Professor, Butler University College of Pharmacy and Health Sciences Ed Hernandez – Executive Vice President, Eli Lilly & Company; President of Manufacturing Operations at Lilly Selected References: Compounded GLP 1 and Dual GIP/GLP 1 Receptor Agonists: A Statement from the American Diabetes Association. Diabetes Care December 2, 2024;  dci240091 https://doi.org/10.2337/dci24-0091 PubMed: 39620926 FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.  US FDA Website ( current as of 12/18/2024)

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Mannkind releases info about it's Afrezza pediatric studies, Dexcom launches AI tech with Stelo, Health Canada approves Tandem/Dexcom G7, diabetes drug may help sleep apnea, an app in development to help drivers with T1D and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Mannkid expects to talk to the FDA about Afrezza inhaled insulin for pediatric approval early in 2025. The company just announced six-month results from its Phase 3 INHALE-1 study of kids aged 4-17 with type 1 or type 2 diabetes comparing either inhaled pre-meal insulin or multiple daily injections (MDI) of rapid-acting insulin analog, both in combination with basal insulin. A 26-week extension phase in which all remaining MDI patients were switched to inhaled insulin is ongoing. HbA1c change over 26 weeks exceeded the prespecified non-inferiority margin of 0.4% (0.435%), largely driven by the variability of a single patient who did not adhere to the study protocol. A modified ITT (mITT) analysis, which excluded this subject, did not exceed the predetermined threshold of 0.4% (0.370%), thereby establishing the non-inferiority of Afrezza to MDI, which was the primary endpoint of the study. Over 26 weeks of treatment, there were no differences in lung function parameters between the treatment groups, There were no differences between groups or concerns in other safety measures, including hypoglycemia. https://www.medscape.com/viewarticle/inhaled-insulin-benefits-kids-diabetes-too-2024a1000nex   XX Dexcom announces the use of AI for its Stelo platform. The company says the new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between lifestyle choices and glucose levels while providing actionable insights to help improve metabolic health. Stelo users will start seeing the features this week. The AI is modeled after Google Cloud's Vertex AI and Gemini models. We'll hear more about this in January – Dexcom will be part of a panel at the Consumer Electronics Show about AI and healthcare. BTW this press release is the first time I've seen what seems to be a new slogan for Dexcom – Discover What You're Made Of. https://www.businesswire.com/news/home/20241217011997/en/Dexcom-Launches-the-First-Generative-AI-Platform-in-Glucose-Biosensing XX Staying with Dexcom, users report that the geofencing issue we reported on seems to be resolved. Previously, if you had an issue with Dexcom G7 outside of your home country, you couldn't reinstall or use the app without customer support. With the latest iOS and Android G7 apps, this seems to be resolved. This is according to the folks in the DIY community who first brought it to my attention.   XX Interesting insulin development to watch. Egypt approves EVA Pharma's insulin drug products, which is a collbaration between Eli llly and EVA, an Egyptian company. The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the collaboration aims to deliver a sustainable supply of high-quality, affordable human and analog insulin to at least one million people annually living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are in Africa.   Lilly has been supplying its active pharmaceutical ingredient (API) for insulin to EVA Pharma at a significantly reduced price and providing pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges. This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality health care for 30 million people living in resource-limited settings annually by 2030. https://www.prnewswire.com/news-releases/lilly-and-eva-pharma-announce-regulatory-approval-and-release-of-locally-manufactured-insulin-in-egypt-302333269.html     XX Can we add treating sleep apnea to the list of applications for terzepatide? That's the generic for Zepbound and Mounjaro. Phase 3 study shows that 10- and 15-milligram injections of Zepbound "significantly reduced the apnea-hypopnea index" among those who have obesity and moderate-to-severe obstructive sleep apnea. Eli Lilly said there was nearly a 20% reduction in weight among those in the trials. The company said it plans to submit its findings to the Food and Drug Administration and other global regulatory agencies beginning mid-year. https://www.aol.com/popular-weight-loss-drug-could-131507702.html   XX Health Canada okays Tandem's tslim X2 with Dexcom G7 and G6 making it the first and only insulin pump in Canada that is integrated with both Dexcom sensors. Now, t:slim X2 users in Canada can experience even more choice when it comes to CGM compatibility, along with the option to spend more time in closed loop with Dexcom G7's 30-minute sensor warm-up time, faster than any other CGM on the market.3 In addition, t:slim X2 users who pair Dexcom G7 with an Apple smartwatch4 can see their glucose numbers directly from their watch without having to access their pump or smartphone4. Tandem will email all in-warranty t:slim X2 users in Canada with instructions on how to add the new compatibility feature free of charge via remote software update. t:slim X2 pumps pre-loaded with the updated software will begin shipping to new customers in early January 2025.   To check coverage and start the process of getting a Tandem insulin pump, please visit tandemdiabetes.ca. https://www.businesswire.com/news/home/20241210731189/en/Tandem-tslim-X2-Insulin-Pump-Now-Compatible-with-Dexcom-G7-CGM-in-Canada XX A federal jury on Tuesday awarded Insulet $452 million in its patent skirmish with EOFlow over insulin patch pumps. The jury awarded Insulet $170 million in compensatory damages from EOFlow and an additional $282 million in exemplary damages for willful and malicious misappropriation. A judge has not yet entered a judgment on the decision. Insulet filed a lawsuit in the U.S. District Court for the District of Massachusetts in 2023, claiming EOFlow copied patented components of its Omnipod insulin pumps. In October 2023, the Massachusetts district court issued a preliminary injunction against EOFlow. Following that decision, Medtronic called off plans to buy EOFlow for about $738 million.   A federal appeals court later overturned the preliminary injunction, and EOFlow resumed selling its devices in Europe. The company recently defended against a separate injunction filed by Insulet in Europe's Unified Patent Court, according to Korea Biomedical Review, an online English newspaper based in Seoul, South Korea.   The Massachusetts jury found this week that EOFlow and CEO Jesse Kim, as well as two of three former Insulet employees who were named as defendants in the lawsuit, misappropriated Insulet's trade secrets.   Insulet CEO Jim Hollingshead said the company is “extremely pleased with the jury's verdict.” EOFlow did not immediately respond to a request for comment. https://www.medtechdive.com/news/insulet-eoflow-jury-verdict-patent-lawsuit/734745/ XX A tele-education program for health care providers who treat people with diabetes resulted in significant improvements in patient outcomes, including better blood sugar levels and increased use of medical devices to manage the disease, a University of Florida study finds. Led by researchers in the UF College of Public Health and Health Professions and the UF College of Medicine, the program used the Extension for Community Health Care Outcomes model, which has been adopted worldwide to train clinicians who treat patients with a variety of conditions. Known as Project ECHO, this is one of the first to demonstrate patient benefits for the program in a large, randomized trial. The findings appear in the journal Diabetes Care. https://ufhealth.org/news/2024/clinician-training-program-leads-to-better-outcomes-for-patients-with-diabetes XX New app under development to make driving safer for people with diabetes. Diabetes Driving Pal says it will use CGM data and guide you while you are driving without any annoying alerts. Guidance/suggestions will be on your car dashboard so that you don't have to look at phone and it will be very individualized and actionable. In a study last year, ~70% of people have reported (5% reported accident) to have at least one low blood sugar while driving and most reported that CGM alerts were not enough to protect them. We are hoping to start beta testing in a few months. We are trying to raise the fund to develop this product. We need your support. For more information, please visit: https://lnkd.in/gTDhnDc4 XX I'm also going to link to the top ten most read diabetes and endocrinology stories of 2024 from Medscape. This is almost all GLP-1 related.. and mostly for people with type 2. https://www.medscape.com/viewarticle/icymi-top-10-diabetes-endocrinology-stories-2024-2024a1000n6u?&icd=login_success_email_match_fpf XX That's it for the last In the News of 2024! Don't miss out episode next week with a look ahead to what we're watching in 2025. I'm SS I'll see you back here soon…

Want to add a healthy habit to your daily routine that is absolutely free and incredibly effective? Looking to reduce insulin resistance and lose visceral fat? Want to boost mental health and improve cognitive function? Look no further than walking! Tune in to hear us unpack the myriad of research-supported benefits.   In this episode, we discuss the incredible benefits of walking, from lowering blood pressure to improving heart rate variability to reducing stress and so much more. Learn about the magic number when it comes to step count, our thoughts on walking in nature vs. on a treadmill, and get practical tips for getting those steps!    Also in this episode:  Naturally Nourished Teas are buy 3 get 1 FREE, use code FREETEA Gift cards at Naturally Nourished Detox Masterclass 1/8 Keto Masterclass 1/15 Walking Pad C2 use code ALIMILLERRD for savings Health Benefits of Walking Lowers Blood Pressure Hypertension: Brisk walking for 30 minutes, five days a week reduces blood pressure (Hypertension, 2020). Improves Cholesterol Levels Cholesterol: Effects on LDL and HDL cholesterol (Journal of the American Heart Association, 2021). Lipid Profiles: Walking improves triglycerides and HDL (Atherosclerosis, 2021). Reduces the Risk of Coronary Artery Disease Coronary Artery Disease Risk: 150 minutes of walking weekly (Circulation, 2022). Enhances Cardiorespiratory Fitness Reduces Systemic Inflammation Systemic Inflammation: Walking lowers CRP and IL-6 (Arteriosclerosis, Thrombosis, and Vascular Biology, 2020). Systemic Inflammation: Walking reduces inflammatory cytokines (The Journal of Endocrinology, 2022). Helps Maintain Healthy Weight and Prevent Obesity Improves Heart Rate Variability Heart Rate Variability: HRV improvement with regular walking (Heart, 2022). Prevents Peripheral Artery Disease Peripheral Artery Disease: Walking improves circulation and function in PAD patients (Journal of Vascular Surgery, 2021). Reduces Resting Heart Rate Enhances Endothelial Function Supports Recovery After Cardiac Events Improves Insulin Sensitivity Insulin Sensitivity: Improvements with post-meal walks (Diabetes Care, 2021). Enhances Glucose Regulation Boosts Fat Oxidation Fat Oxidation: Brisk walking boosts fat metabolism (Journal of Applied Physiology, 2022). Reduces Visceral Fat Reduction of visceral fat after 10,000 steps/day (Obesity, 2021). Promotes Energy Balance Energy Balance: 12,000 steps/day for maintaining weight (Medicine & Science in Sports & Exercise, 2020). Regulates Hormones Related to Metabolism Increases Mitochondrial Efficiency Improves Metabolic Flexibility Prevents Metabolic Syndrome Helps Manage Type 2 Diabetes Mental health Stress Reduction: Nature walks lower cortisol more than treadmill (Environmental Research, 2022). Stimulates Neurogenesis and Brain Plasticity Brain Connectivity: Walking improves default mode network activity (Journal of Aging Research, 2021). Enhances Neurotransmitter Balance Supports Autonomic Nervous System Regulation Improves Sensory Integration Vestibular Function: Enhancing balance and stability with walking (Frontiers in Neuroscience, 2021). Strengthens Cognitive Function Neurogenesis and Cognitive Function: Exercise-induced brain growth (Nature Neuroscience, 2021). Promotes Myelination and Nerve Health Enhances Emotional Regulation via the Vagus Nerve Reduces Neurological Disease Risk Synchronizes the Nervous System Through Rhythmic Movement Improves Sleep and Circadian Rhythm Bone and Joint Health Immune System Support Longevity and Reduced Mortality Gut Health Gut Health: Positive effects on microbiota diversity (Gut Microbes, 2020). The Science of Step Counts Thoughts on Nature vs. Treadmill Walking Cognitive Benefits: Nature walking improves attention restoration (Nature Neuroscience, 2021). Proprioception: Benefits of uneven terrain in natural settings (Journal of Sports Medicine, 2023). Motivation: Outdoor walkers maintain habits better than treadmill users (Behavioral Medicine, 2022). Immune Boosting: Increased NK cell activity in forest walkers (International Journal of Environmental Health Research, 2021).   Sponsors for this episode:  According to extensive research by the Environmental Working Group, virtually every home in America has harmful contaminants in its tap water. That's why you've got to check out AquaTru. AquaTru purifiers use a 4-stage reverse osmosis purification process, and their countertop purifiers work with NO installation or plumbing. It removes 15x more contaminants than ordinary pitcher filters and are specifically designed to combat chemicals like PFAS in your water supply. Naturally Nourished Podcast listeners can use code ALIMILLERRD at AquaTru.com to save 20% off. 

Join us as we sit down with Gary Marc Rothenberg, a podiatrist, to explore the unique connections between Olympic-level perseverance and the day-to-day challenges of chronic disease management, specifically diabetes. We discuss how celebrating small victories, integrating mental health care, and addressing social determinants of health can inspire better patient outcomes. Gary Marc Rothenberg is a podiatrist. He discusses the KevinMD article, "Celebrating silver: 3 best practices for meeting people where they are with diabetes adherence." Our presenting sponsor is DAX Copilot by Microsoft. Do you spend more time on administrative tasks like clinical documentation than you do with patients? You're not alone. Clinicians report spending up to two hours on administrative tasks for each hour of patient care. Microsoft is committed to helping clinicians restore the balance with DAX Copilot, an AI-powered, voice-enabled solution that automates clinical documentation and workflows. 70 percent of physicians who use DAX Copilot say it improves their work-life balance while reducing feelings of burnout and fatigue. Patients love it too! 93 percent of patients say their physician is more personable and conversational, and 75 percent of physicians say it improves patient experiences. Help restore your work-life balance with DAX Copilot, your AI assistant for automated clinical documentation and workflows. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://www.kevinmd.com/cme I'm partnering with Learner+ to offer clinicians access to an AI-powered reflective portfolio that rewards CME/CE credits from meaningful reflections. Find out more: https://www.kevinmd.com/learnerplus

In this episode, we discuss the efficacy and safety of semaglutide and tirzepatide for weight loss with a particular focus on the legal, regulatory, and safety aspects of these “compounded” GLP-1 receptor agonist medications. Key Concepts Semaglutide and tirzepatide have growing evidence that their clinical benefits extend beyond the treatment of diabetes. Evidence now shows benefit in a variety of obesity-related disease states regardless of a patient's diabetes status. Insurance coverage and drug cost is a major barrier to these medications, with cash prices exceeding $1000 per month in the US. There are many companies that are combining telemedicine visits with “compounded” GLP-1s to provide these medications at a reduced cost. The Food, Drug, and Cosmetic (FD&C) Act regulates compounded drugs. These regulations provide the legal context for pharmacies to compound GLP-1 medications. These regulations describe who can compound, what drugs can be compounded, and other unique circumstances (e.g. compounding in the context of a drug shortage). The FDA has released warnings regarding safety risks of compounded GLP-1s. The main safety concern is dosing errors; however, the warnings also include concerns of patients accessing drug products that are outside of the legal scope of the FD&C Act. The recent ADA statement recommends against the use of compounded GLP-1s due to these concerns. References Karagiannis T, Malandris K, Avgerinos I, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. 2024;67(7):1206-1222. doi:10.1007/s00125-024-06144-1 Müllertz ALO, Sandsdal RM, Jensen SBK, Torekov SS. Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obes Rev. 2024;25(5):e13717. doi:10.1111/obr.13717 Jastreboff AM, Le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine. 2024. https://www.nejm.org/doi/full/10.1056/NEJMoa2410819 Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-P). https://www.cms.gov/newsroom/fact-sheets/contract-year-2026-policy-and-technical-changes-medicare-advantage-program-medicare-prescription Human Drug Compounding. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/media/98973/download FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss Nomination of Semaglutide Products to the Demonstrable Difficulties for Compounding Lists. https://www.regulations.gov/document/FDA-2017-N-2562-0029 Neumiller JJ, Bajaj M, Bannuru RR, et al. Compounded GLP 1 and dual GIP/GLP 1 receptor agonists: A statement from the American Diabetes Association. Diabetes Care. 2024 Dec 2:dci240091. doi: 10.2337/dci24-0091.

During a special episode of The Huddle recorded live at our 2024 annual meeting, we sat down with incoming ADCES President Veronica Brady, PhD, FNP-BC, BC-ADM, CDCES, FADCES. Veronica discussed the impact she wants to leave behind as President this coming year, as well as the concept of unconscious bias, how it shows up in our everyday lives and in working as health care professionals, and how we can practice cultural humility to better serve the needs of people with and at risk for diabetes. Please note: since the recording of this episode, Kirsten Yehl has since moved on from ADCES to pursue another professional opportunity. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.     Association of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes 2.     Increasing Medication Use and Polypharmacy in Type 2 Diabetes 3.     Association of Energy Intake and Dietary Glycemic Load in Different Time Periods With Cardiovascular Disease Mortality Among U.S. Adults With Type 2 Diabetes 4.     Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout 5.     GLP-1 Receptor Agonists and the Path to Sustainable Obesity Care   For more information about each of ADA's science and medical journals, please visit.www.diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health

In this controversial episode, Melanie dives into the research and health claims behind the growing-in-popularity Carnivore Diet, including the claim it can help prevent kidney stones. Blog: Why is Evidence Based Nutrition So Important?  Blog: Can Too Much Protein Cause Kidney Stones?   Ermer T, Nazzal L, Tio MC, Waikar S, Aronson PS, Knauf F. Oxalate homeostasis. Nat Rev Nephrol. 2023 Feb;19(2):123-138. Hu FB. Plant-based foods and prevention of cardiovascular disease: an overview. The American Journal of Clinical Nutrition. 2003;78(3):544S-551S. Mohamadi A, Shiraseb F, Mirzababaei A, et al. Circulating Inflammatory Markers May Mediate the Relationship between Healthy Plant-Based Diet and Metabolic Phenotype Obesity in Women: A Cross-Sectional Study. International Journal of Clinical Practice. 2022;2022(1):8099382. Suarez-Lledo V, Alvarez-Galvez J Prevalence of Health Misinformation on Social Media: Systematic Review. J Med Internet Res 2021;23(1):e17187 Turner KM, Keogh JB, Meikle PJ, Clifton PM. Changes in Lipids and Inflammatory Markers after Consuming Diets High in Red Meat or Dairy for Four Weeks. Nutrients. 2017 Aug 17;9(8):886. Wilson HE, Moe SM. You are what you eat: should it be all meat? FR-PO1072. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2024; October 25, 2024;San Diego, California. (referenced in Docwire News) Zhangling Chen, Jean-Philippe Drouin-Chartier, Yanping Li, Megu Y. Baden, JoAnn E. Manson, Walter C. Willett, Trudy Voortman, Frank B. Hu, Shilpa N. Bhupathiraju; Changes in Plant-Based Diet Indices and Subsequent Risk of Type 2 Diabetes in Women and Men: Three U.S. Prospective Cohorts. Diabetes Care 1 March 2021; 44 (3): 663–671.   Submit a question for Melanie to answer on the podcast! Connect with The Kidney Dietitian! Work with Us! |  Instagram | Facebook | Pinterest | Facebook Group | Newsletter www.thekidneydietitian.org All information in this podcast is meant for educational purposes only and should not be used in place of advice from a medical professional.  

GLP-1s have revolutionized how we think about and treat obesity. But that wasn't what they were originally intended for. Mentioned in this episode:American Diabetes Organization (diabetes.org)National Institute of Diabetes, Digestive and Kidney Diseases (niddk.nih.gov)For more Nutrition Diva content centered around Diabetes, check out this special Spotify playlist here!Nutrition Diva is hosted by Monica Reinagel, MS, LDN.  Transcripts are available at Simplecast. Have a nutrition question? Send an email to nutrition@quickanddirtytips.com or leave a voicemail at 443-961-6206.Follow Nutrition Diva on Facebook and subscribe to the newsletter for more diet and nutrition tips. Find Monica's blog and other programs at Nutrition Over Easy. Nutrition Diva is a part of the Quick and Dirty Tips podcast network. LINKS:Transcripts: https://nutrition-diva.simplecast.com/episodes/Facebook: https://www.facebook.com/QDTNutrition/Newsletter: https://www.quickanddirtytips.com/nutrition-diva-newsletterNutrition Over Easy: https://nutritionovereasy.comQuick and Dirty Tips: https://quickanddirtytipscom

La berberina es uno de los suplementos alimenticios más usados hoy en día. Pero, ¿sirve de algo? ¿hay investigación de calidad que le respalde? ¿sirve para bajar de peso y controlar la glucosa? Esto y más, aprenderás en este episodio de Doctor Mau Informa. Suscríbete a mi podcast en tu plataforma favorita. Anda, hazlo ahora mismo.   #doctormauinforma Suscríbete a mi boletín informativo en: www.drmauriciogonzalez.com/ ⁣ Redes sociales: ⁣ ⁣ YouTube: /@doctormauinforma Instagram: www.instagram.com/dr.mauriciogonzalez TikTok: www.tiktok.com/@drmauriciogonzalez Twitter: www.twitter.com/DrMauricioGon CONTACTO ► booking@drmauriciogonzalez.com ¡Nos escuchamos pronto!⁣ Fuentes:    Li Z, Wang Y, Xu Q, et al. Berberine and health outcomes: An umbrella review. Phytother Res. 2023;37(5):2051-2066. doi:10.1002/ptr.7806 Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med. 2012;2012:591654. doi:10.1155/2012/591654 Diabetes Prevention Program Research Group. Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2019;42(4):601-608. doi:10.2337/dc18-1970 Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35(4):731-737. doi:10.2337/dc11-1299   Learn more about your ad choices. Visit megaphone.fm/adchoices

Today, we're diving into the intersection of diabetes and the healthcare system with an incredible guest – Natalie Bellini, who brings over 50 years of lived experience with type 1 diabetes and expertise from the forefront of diabetes care. As an Endocrine Nurse Practitioner, Certified Diabetes Care and Education Specialist (CDCES), and Program Director for Diabetes Technology at University Hospitals in Cleveland, Natalie is also the host of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives. Throughout her career, she has been a trailblazer in advancing diabetes care, publishing studies on topics like GLP-1s and groundbreaking diabetes technology, and speaking nationally and globally to advocate for the community. In this episode, we discuss key issues in the doctor-patient relationship and what needs to change, the role of technology in improving outcomes when patients are empowered with education, the challenges many people with type 1 diabetes face, and the critical importance of early screening for type 1.Time Stamps:  (02:58) "Diabetes kind of found me, I didn't find it." (03:30) The Evolution of Natalie's Career (05:57) Being Diagnosed 50+ Years Ago & the Technological Advances Made Since (12:50) How the Education Around T1D and the Complications Have Changed(14:00) Balancing Patient Care with Healthcare System Demands  & The Growing Crisis of T1D Misdiagnosis with Adults. (16:00) Emotional and Psychological Aspects of Diabetes Management(16:41) Barriers to Effective Diabetes Management (19:54) “You should never say you're fine when you walk into an endo's office.”(20:25) Why So Many T1Ds Are Still Struggling (With or Without Technology) (32:00) The Importance of Addressing Emotions in Diabetes Management(34:55) The Truth About AID (40:26) The Importance of Early Detection(41:00) “In the US, they are recommending first-degree relatives be screened and people aren't doing a great job of it because we need to educate the right people.” (42:26) The Science of Understanding Antibodies (52:49) Finding the Support You Deserve What to do now:Follow me @lauren_bongiorno and @riselyhealth on Instagram to stay in the loop when new episodes drop.Doors are open for the January 2025 round of our signature group coaching program. Apply for coaching and talk to our team so you can reclaim the life you deserve. Be ready to treat very low blood sugar with Gvoke HypoPen® (glucagon injection). To find out more, go to GvokeGlucagon.com/RiselySee Important Safety Information: https://www.gvokeglucagon.com/#important-safety-informationSee Full Prescribing Information: https://bit.ly/3baHqAODisclaimer: Nothing you hear on the Reclaim your Rise podcast should be a substitute for personalized professional medical advice. Please always consult your physician or other medical professional before making any changes to your diet, insulin dosages, or healthcare plan.